ଡକ୍ସୋରୁବିସିନ

ଡକ୍ସୋରୁବିସିନ
Clinical data
Pronunciation	/ˌdɒksəˈruːbɪsɪn/
Trade names	Adriamycin, Doxil, Caelyx, Myocet, others
AHFS/Drugs.com	monograph
MedlinePlus	a682221
Pregnancy; category	AU: D ; US: D (Evidence of risk) ; ;
Routes of; administration	intravenous, intravesical
ATC code	L01DB01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	5% (by mouth)
Protein binding	75%
Metabolism	Liver
Elimination half-life	Triphasic; 12 minutes, 3.3 hours, 30 hours. Mean: 1-3 hours
Excretion	Urine (5-12%), faeces (40-50%)
Identifiers
	IUPAC name (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;
CAS Number	23214-92-8 ;
PubChem CID	31703;
IUPHAR/BPS	7069;
DrugBank	DB00997 ;
ChemSpider	29400 ;
UNII	80168379AG;
KEGG	D03899 ;
ChEBI	CHEBI:28748 ;
ChEMBL	CHEMBL53463 ;
ECHA InfoCard	100.041.344
Chemical and physical data
Formula	C27H29NO11
Molar mass	543.52 g/mol
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O;
	InChI InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27 (36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23 (32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15, 17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1 ; Key:AOJJSUZBOXZQNB-TZSSRYMLSA-N ;
(what is this?) (verify)

ଡକ୍ସୋରୁବିସିନ (ଇଂରାଜୀ ଭାଷାରେ Doxorubicin, ବିକ୍ରୟ ନାମ ଆଡ୍ରିଆମାଇସିନ) ଏକ କେମୋଥେରାପି ଔଷଧ (chemotherapy medication) ଯାହା କର୍କଟ ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ବ୍ୟବ‌ହାର କରାଯାଏ । ସ୍ତନ କର୍କଟ, ମୂତ୍ରାଶୟ କର୍କଟ (bladder cancer), କାପୋସି ସାର୍କୋମା (Kaposi's sarcoma), ଲିମ୍ଫୋମା ଓ ଆକ୍ୟୁଟ ଲିମ୍ପୋସାଇଟିକ ଲିଉକେମିଆ (acute lymphocytic leukemia) ଇତ୍ୟାଦି ରୋଗମାନଙ୍କୁ ମୂଖ୍ୟତଃ ଏହା ସାହାଯ୍ୟରେ ଚିକିତ୍ସା କରାଯାଏ । ଅଧିକାଂଶ ସମୟରେ ଅନ୍ୟାନ୍ୟ କେମୋଥେରାପି ଔଷଧ (together with other chemotherapy agents) ସ‌ହିତ ଏହା ଦିଆଯାଏ । ଡକ୍ସୋରୁବିସିନ ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ (injection into a vein) ଆକାରରେ ଦିଆଯାଏ ।^[୩]

ଏହାର ପ୍ରତିକ୍ରିୟାରେ କେଶ ହାନି (hair loss), ଅସ୍ଥିମଜ୍ଜା ଦମନ (bone marrow suppression), ବାନ୍ତି, ରାସ୍ ଓ ପାଟି ପ୍ରଦାହ (inflammation of the mouth) ଆଦି ଦେଖାଯାଏ । ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ସାଂଘାତିକ ହେଲେ ଆନାଫାଇଲାକ୍‌ସିସ ଭଳି ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା, ହୃତ୍‌ପିଣ୍ଡ କ୍ଷତି (heart damage), ଇଞ୍ଜେକସନ ଦେବା ସ୍ଥାନରେ ତନ୍ତୁ ନଷ୍ଟ, ରାଡିଏସନ ଦଗ୍ଧ (radiation recall) ଓ ଚିକିତ୍ସା ସମ୍ବନ୍ଧୀୟ ଲିଉକେମିଆ ହୋଇପାରେ । କିଛି ଦିନ ପାଇଁ ପରିସ୍ରା ଗାଢ଼ ରଙ୍ଗର ହୋଇପାରେ । ଡକ୍ସୋରୁବିସିନ ଏକ ଆନ୍ଥ୍ରାସାଇକ୍ଲିନ (anthracycline) ଓ ଆଣ୍ଟିଟ୍ୟୁମର (antitumor antibiotic) ଶ୍ରେଣୀର ଔଷଧ ।^[୩] ଏହା ଡିଏନଏ DNA କାର୍ଯ୍ୟକୁ ବାଧା ପ୍ରଦାନ କରେ ।^[୪]

ସନ ୧୯୭୪ରେ ଡାକ୍ତରୀ ଚିକିତ୍ସାରେ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ଡକ୍ସୋରୁବିସିନ ଔଷଧ ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୩] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ (World Health Organization's List of Essential Medicines) ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ (health system) ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୫] ବିକାଶଶୀଳ ଦେଶମାନଙ୍କରେ (developing world) ଏହି ଔଷଧର ଏକ ୫୦ମି:ଗ୍ରା: ଭାଏଲର ହୋଲସେଲ କ୍ରୟ ମୂଲ୍ୟ ୩.୮୮ରୁ ୩୨.୭୯ ଆମେରିକୀୟ ଡଲାର ।^[୬] ସଂଯୁକ୍ତ ରାଷ୍ଟ୍ରରେ ସମ ପରିମାଣ ଔଷଧର ମୂଲ୍ୟ ୧୦୦.୧୨ ପାଉଣ୍ଡ ।^[୭]^[୮] ଏହାର ପେଜିଲେଟେଡ (pegylated) ଓ ଲାଇପୋସୋମସ୍ (liposomes) ସଂସ୍କରଣ ମଧ୍ୟ ମିଳେ କିନ୍ତୁ ଏହା ଅଧିକ ଦାମିକିଆ ।^[୮] ମୂଳରୂପରେ ଏହା ସ୍ଟ୍ରେପ୍ଟୋମାଇସେସ ପିଉସେଟିଅସ (Streptomyces peucetius) ଜୀବାଣୁରୁ ପ୍ରସ୍ତୁତ କରାଯାଉଥିଲା । ^[୯]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "(doxorubicin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 15 April 2014.
↑ Brayfield, A, ed. (19 December 2013). "Doxorubicin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Doxorubicin Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 12 January 2017.
↑ Tacar, O; Sriamornsak, P; Dass, CR (February 2013). "Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems". The Journal of Pharmacy and Pharmacology. 65 (2): 157–70. doi:10.1111/j.2042-7158.2012.01567.x. PMID 23278683.
↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
↑ "Doxorubicin HCL". International Drug Price Indicator Guide. Retrieved 8 December 2016.^{[permanent dead link]}
↑ "Doxorubicin: British National Formulary". BNF. Archived from the original on 2012-08-30. Retrieved 6 March 2017.
↑ ^୮.୦ ^୮.୧ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 583. ISBN 9780857111562.
↑ Ravina, Enrique (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs (in ଇଂରାଜୀ). John Wiley & Sons. p. 291. ISBN 9783527326693.

[MSR-1] ୧.୦ ^୧.୧ ^୧.୨ "(doxorubicin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 15 April 2014.

[MD-2] Brayfield, A, ed. (19 December 2013). "Doxorubicin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.

[AHFS2017-3] ୩.୦ ^୩.୧ ^୩.୨ "Doxorubicin Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 12 January 2017.

[Ta2013-4] Tacar, O; Sriamornsak, P; Dass, CR (February 2013). "Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems". The Journal of Pharmacy and Pharmacology. 65 (2): 157–70. doi:10.1111/j.2042-7158.2012.01567.x. PMID 23278683.

[WHO19th-5] "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.

[ERC2014-6] "Doxorubicin HCL". International Drug Price Indicator Guide. Retrieved 8 December 2016.^{[permanent dead link]}

[7] "Doxorubicin: British National Formulary". BNF. Archived from the original on 2012-08-30. Retrieved 6 March 2017.

[BNF69-8] ୮.୦ ^୮.୧ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 583. ISBN 9780857111562.

[9] Ravina, Enrique (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs (in ଇଂରାଜୀ). John Wiley & Sons. p. 291. ISBN 9783527326693.

[୩]

[୧]

[୨]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]